MarketCap
Facebook
X
Telegram
Enzo Biochem Total Liabilities | ENZ
Annual Total Liabilities Enzo Biochem
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.7 M | 43.4 M | 21.1 M | 45.1 M | 54.2 M | 20.6 M | 20.5 M | 18.8 M | 22.3 M | 25.8 M | 27.5 M | 24.8 M | 20 M | 20.8 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 54.2 M | 18.8 M | 28.2 M |
Quarterly Total Liabilities Enzo Biochem
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.1 M | 20.9 M | 27.6 M | 27.6 M | 29.7 M | 24.4 M | 28.3 M | 32 M | 43.4 M | 53.1 M | 43.7 M | 40.2 M | 41.4 M | 41.7 M | 50.2 M | 41.4 M | 45.1 M | 45.1 M | 45.9 M | 54.5 M | 54.2 M | 54.2 M | 21.6 M | 46.9 M | 20.6 M | 20 M | 20.4 M | 18.5 M | 20.5 M | 20.5 M | 18.7 M | 20.1 M | 18.8 M | 18.8 M | 26.5 M | 22 M | 22.3 M | 22.3 M | 24.7 M | 27.2 M | 25.8 M | 25.8 M | 23.5 M | 26.5 M | 27.5 M | 27.5 M | - | 25.2 M | 24.8 M | 24.8 M | - | 20 M | 20 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 54.5 M | 18.5 M | 30.3 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
QIAGEN N.V.
QGEN
|
3.11 B | - | - | $ 10.6 B |  Niderland |
 |
Centogene N.V.
CNTG
|
58.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Charles River Laboratories International
CRL
|
3.92 B | $ 288.5 | 0.54 % | $ 14.3 B |  USA |
 |
Aspira Women's Health
AWH
|
12.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
DarioHealth Corp.
DRIO
|
7.26 M | $ 7.24 | 3.72 % | $ 28.8 M |  Israel |
 |
Brainsway Ltd.
BWAY
|
14.4 M | $ 14.15 | 1.61 % | $ 481 M | Israel |
 |
Celcuity
CELC
|
366 M | $ 95.7 | 0.44 % | $ 4.47 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
1.83 M | - | - | $ 9.42 M | Israel |
|
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
84.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
22 M | - | -13.05 % | $ 7.29 M | USA |
 |
Global Cord Blood Corporation
CO
|
3.65 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
4.36 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
427 M | - | 0.12 % | $ 80.1 M | China |
 |
Chembio Diagnostics
CEMI
|
44.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | USA |
 |
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.16 B | $ 237.14 | 2.07 % | $ 26.3 B | USA |
 |
DexCom
DXCM
|
3.59 B | $ 87.9 | 0.02 % | $ 34.3 B | USA |
 |
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
7.08 B | $ 164.85 | 0.78 % | $ 12.9 B |  Irlanda |
 |
Soleno Therapeutics
SLNO
|
114 M | - | - | $ 2.69 B | USA |
 |
Psychemedics Corporation
PMD
|
3.19 M | - | -1.84 % | $ 15.3 M | USA |
 |
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K | Israel |
 |
Syneos Health
SYNH
|
4.7 B | - | - | $ 4.46 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.76 B | $ 326.89 | 0.29 % | $ 27.2 B | USA |
 |
Invitae Corporation
NVTA
|
1.85 B | - | - | $ 21.2 M | USA |
 |
Organovo Holdings
ONVO
|
8.48 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
6.2 M | - | -16.95 % | $ 1.54 M | USA |
 |
T2 Biosystems
TTOO
|
62.8 M | - | -39.35 % | $ 313 K | USA |
 |
Anixa Biosciences
ANIX
|
2.13 M | $ 3.07 | 0.66 % | $ 99.6 K | USA |
 |
PerkinElmer
PKI
|
4.92 B | - | -0.91 % | $ 14.7 B | USA |
 |
Meridian Bioscience
VIVO
|
135 M | - | - | $ 1.49 B | USA |
 |
Quotient Limited
QTNT
|
338 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Mettler-Toledo International
MTD
|
3.74 B | $ 1 345.26 | 0.11 % | $ 27.7 B | Schweiz |
 |
Myriad Genetics
MYGN
|
339 M | $ 3.18 | 1.57 % | $ 294 M | USA |
 |
ENDRA Life Sciences
NDRA
|
1.59 M | $ 6.05 | 6.51 % | $ 4.76 M | USA |
 |
National Research Corporation
NRC
|
121 M | $ 21.53 | 1.32 % | $ 482 M | USA |
 |
Renalytix AI plc
RNLX
|
15.8 M | - | 5.66 % | $ 22.7 M | Britain |
 |
Interpace Biosciences
IDXG
|
11.5 M | $ 1.45 | 2.11 % | $ 6.41 M | USA |
 |
OPKO Health
OPK
|
664 M | $ 1.64 | 1.86 % | $ 1.23 B | USA |
 |
Pacific Biosciences of California
PACB
|
779 M | $ 1.35 | 3.85 % | $ 405 M | USA |
 |
IQVIA Holdings
IQV
|
23.3 B | $ 267.77 | 2.95 % | $ 46 B | USA |
 |
Surmodics
SRDX
|
59.7 M | - | - | $ 608 M | USA |
 |
Personalis
PSNL
|
73 M | $ 17.2 | 2.2 % | $ 1.53 B | USA |
 |
Quidel Corporation
QDEL
|
538 M | $ 13.97 | 0.29 % | $ 588 M | USA |